No Data
Cutting-Edge Cancer Therapies Lead the Way Into a Transformative Year
Oncolytics Biotech Says German Regulatory Approval Received for Full Patient Enrollment in Pancreatic Cancer Study
Oncolytics Biotech Up 6.5% in U.S. Pre-Market as Germany Approves Continuing GOBLET Enrollment
Express News | Oncolytics Biotech Says Germany's Medical Regulatory Body, The Paul-Ehrlich-Institute (PEI), Has Approved The Continuation Of Patient Enrollment Into Cohort 5 Of The GOBLET Study
Oncolytics Biotech Brief: Says Regulatory Approval Clears Path for Co to Advance "Promising" Pancreatic Cancer Treatment, Following a Review of Safety Data
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?
No Data